FY2024 EPS Estimates for Avantor Lowered by Zacks Research

Avantor, Inc. (NYSE:AVTR) – Equities research analysts at Zacks Research reduced their FY2024 earnings estimates for shares of Avantor in a research report issued on Friday, November 15th. Zacks Research analyst D. Dey now anticipates that the company will post earnings of $0.98 per share for the year, down from their previous forecast of $1.01. The consensus estimate for Avantor’s current full-year earnings is $0.98 per share. Zacks Research also issued estimates for Avantor’s Q4 2024 earnings at $0.25 EPS, Q1 2025 earnings at $0.25 EPS, Q2 2025 earnings at $0.27 EPS, Q4 2025 earnings at $0.31 EPS, FY2025 earnings at $1.10 EPS, Q2 2026 earnings at $0.28 EPS and FY2026 earnings at $1.27 EPS.

Several other equities research analysts have also issued reports on AVTR. Stifel Nicolaus lifted their price target on Avantor from $27.00 to $28.00 and gave the company a “buy” rating in a report on Monday, July 29th. UBS Group reduced their target price on shares of Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a research note on Tuesday, October 8th. Robert W. Baird dropped their price target on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th. Wells Fargo & Company reduced their price objective on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, October 28th. Finally, Barclays decreased their price objective on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, Avantor has a consensus rating of “Moderate Buy” and an average target price of $27.57.

Avantor Price Performance

AVTR opened at $20.18 on Monday. The stock has a fifty day moving average price of $24.41 and a 200 day moving average price of $23.97. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84. Avantor has a 1 year low of $19.23 and a 1 year high of $28.00. The stock has a market cap of $13.73 billion, a price-to-earnings ratio of 43.87, a PEG ratio of 2.51 and a beta of 1.35.

Insiders Place Their Bets

In related news, CAO Steven W. Eck sold 3,525 shares of Avantor stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the sale, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at $740,372.64. This trade represents a 10.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Avantor

Hedge funds have recently made changes to their positions in the business. Swedbank AB bought a new stake in Avantor in the first quarter valued at about $2,707,000. Sound Shore Management Inc. CT acquired a new stake in Avantor during the second quarter valued at approximately $76,412,000. Seven Eight Capital LP bought a new stake in shares of Avantor in the 2nd quarter valued at approximately $642,000. New York State Teachers Retirement System acquired a new position in shares of Avantor in the 3rd quarter worth approximately $8,473,000. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Avantor by 35.1% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,157,855 shares of the company’s stock worth $24,547,000 after buying an additional 300,579 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.